Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Synlogic, Inc. (SYBX)
Newly released Crypto mining rig for Synlogic, Inc. coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates
3 days ago | Zacks Investment Research
Synlogic Reports Second Quarter Financial Results and Provides Business Update
3 days ago | PRNewsWire
Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
a week ago | PRNewsWire
Will Synlogic, Inc. (SYBX) Report Negative Q2 Earnings? What You Should Know
2 weeks ago | Zacks Investment Research
Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU)
3 weeks ago | PRNewsWire
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
a month ago | Zacks Investment Research
Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)
a month ago | PRNewsWire
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
a month ago | PRNewsWire
Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
2 months ago | PRNewsWire
Synlogic Reminds Stockholders of 2021 Annual General Meeting Details
2 months ago | PRNewsWire

About:

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Sector:

Healthcare

Industry:

Biotechnology

Address:

Synlogic, Inc. 301 Binney Street Suite 402 Cambridge MA 02142 United States

Website:

Home

Phone:

617-401-9975

Leave a comment

Your email address will not be published. Required fields are marked *